Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Allakos Inc
(NQ:
ALLK
)
1.350
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allakos Inc
< Previous
1
2
3
4
5
Next >
10 Health Care Stocks Whale Activity In Today's Session
November 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
October 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 22, 2024
Via
Benzinga
ALLK Stock Earnings: Allakos Beats EPS for Q2 2024
August 07, 2024
ALLK stock results show that Allakos beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
ALLK Stock Earnings: Allakos Meets EPS for Q1 2024
May 09, 2024
ALLK stock results show that Allakos met analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
ALLK Stock Earnings: Allakos Misses EPS for Q4 2023
March 14, 2024
ALLK stock results show that Allakos missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
October 11, 2024
Via
Benzinga
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
October 10, 2024
From
Allakos Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 04, 2024
Via
Benzinga
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
August 07, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
June 25, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
May 28, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
May 09, 2024
From
Allakos Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 03, 2024
Pre-market stock movers are worth checking out this morning as we dive into all of the biggest news moving shares on Friday!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
May 01, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
April 15, 2024
We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning!
Via
InvestorPlace
3 Biotech Stocks to Dump Before They Go to Zero
April 09, 2024
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling.
Via
InvestorPlace
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
February 26, 2024
From
Allakos Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 14, 2024
Via
Benzinga
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
February 12, 2024
From
Allakos Inc.
Via
GlobeNewswire
Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
January 17, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 17, 2024
Via
Benzinga
Gold Down 1%; PNC Financial Posts Upbeat Earnings
January 16, 2024
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 350 points on Tuesday. The Dow traded down 0.93% to 37,243.85 while the NASDAQ fell 0.58% to 14,885.45. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 16, 2024
Via
Benzinga
Crude Oil Edges Lower; Morgan Stanley Posts Upbeat Revenue
January 16, 2024
U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling more than 150 points on Tuesday. The Dow traded down 0.46% to 37,421.80 while the NASDAQ fell 0.02% to...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Is Allakos (ALLK) Stock Down 57% Today?
January 16, 2024
Allakos stock is falling hard on Tuesday as investors in ALLK react to two of the company's Phase 2 clinical trials failing.
Via
InvestorPlace
Trial Setback: Allakos Drops Lead Skin Disorder Candidate, Cuts Workforce By 50%
January 16, 2024
Allakos reports disappointing topline data from phase 2 trials for lirentelimab in atopic dermatitis and chronic spontaneous urticaria. Company undergoes restructuring to focus on AK006, extending cash...
Via
Benzinga
Dow Dips 200 Points; Goldman Sachs Earnings Top Views
January 16, 2024
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.56% to 37,384.20 while the NASDAQ...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.